Scipio Bioscience

Scipio Bioscience works on the development and industrialization of a first sample preparation kit, designed to democratize single-cell sequencing experiments. They aim at solving the issues faced with current single-cell sequencing solutions, which require specific microfluidics instruments. The need for an instrument involves a heavy investment and carries logistical challenges. Scipio bioscience believes that a simple benchtop kit, affordable for all, will be a game-changer and will drive the single-cell market growth globally. It will enable thousands of researchers is the world, from the academia as well as from private laboratories, to discover key insights in all fields of life sciences, including neurology, oncology, gene-environment interactions.
Scipio Logo Colour
Pierre Walrafen about Verve Ventures
We found the best possible support from Verve Ventures, not only during the fundraising, where Verve Ventures and its investors' questions prompted us to improve our vision and plans, but also since then, through strategic and operational advice provided by Verve Ventures team members on a day to day basis.
Founders / Management Pierre Walrafen, Prof Stuart Edelstein
Sectors Health & Bio, Single-cell, Next Generation Sequencing
Located in Paris
Co-Investors Seventure, M Ventures, HTGF
Follow On

LinkedIn

I am text block. Click edit button to change this text. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

Sign up to receive our weekly newsletter and learn about investing in technologies that are changing the world.